S24.0.1. Integrating Anti-CTLA4 Salvage With Locoregional Therapy After Anti-PD-1 in Liver-Dominant Metastatic ESCC
Questions relevant to contemporary ESCC management will focus on how to optimally sequence therapies after failure of PD-1-base therapy in advanced or metastatic ESCC, how to incorporate liver-directed strategies for liver-dominant disease or oligoprogression, and after a favorable response to ipilimumab plus nivolumab...